Plasma pTau217 as a Prognostic, Risk-Stratification, and Monitoring Biomarker of Clinical Progression in Lewy Body Disease
Sara A. Lorkiewicz, Carla Abdelnour, MacKenzie L. Bolen, Alena M. Smith et autres
Abstract Background and Objectives While plasma phosphorylated tau-217 (pTau217) detects co-occurring Alzheimer’s disease (AD) neuropathologic change in Lewy body disease (LBD), relationships with long-term clinical outcomes remain unclear. Our aim was to evaluate plasma pTau217 as a prognostic, risk-stratification, and monitoring biomarker …
us, es, se, gb (code pays fourni par la source)